RU2011102743A - Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения - Google Patents

Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения Download PDF

Info

Publication number
RU2011102743A
RU2011102743A RU2011102743/15A RU2011102743A RU2011102743A RU 2011102743 A RU2011102743 A RU 2011102743A RU 2011102743/15 A RU2011102743/15 A RU 2011102743/15A RU 2011102743 A RU2011102743 A RU 2011102743A RU 2011102743 A RU2011102743 A RU 2011102743A
Authority
RU
Russia
Prior art keywords
determinants
subject
tumor
sample
level
Prior art date
Application number
RU2011102743/15A
Other languages
English (en)
Russian (ru)
Inventor
Линда ЧИН (US)
Линда ЧИН
Кеннет Л. СКОТТ (US)
Кеннет Л. СКОТТ
Папиа ГХОШ (US)
Папиа ГХОШ
Original Assignee
Дана-Фарбер Кэнсер Инститьют, Инк. (Us)
Дана-Фарбер Кэнсер Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дана-Фарбер Кэнсер Инститьют, Инк. (Us), Дана-Фарбер Кэнсер Инститьют, Инк. filed Critical Дана-Фарбер Кэнсер Инститьют, Инк. (Us)
Publication of RU2011102743A publication Critical patent/RU2011102743A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2011102743/15A 2008-06-26 2009-06-26 Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения RU2011102743A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7593308P 2008-06-26 2008-06-26
US61/075,933 2008-06-26

Publications (1)

Publication Number Publication Date
RU2011102743A true RU2011102743A (ru) 2012-08-10

Family

ID=41445345

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011102743/15A RU2011102743A (ru) 2008-06-26 2009-06-26 Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения

Country Status (14)

Country Link
US (1) US20110182881A1 (enExample)
EP (1) EP2307886A2 (enExample)
JP (1) JP2011526693A (enExample)
KR (1) KR20110036056A (enExample)
CN (1) CN102132160A (enExample)
AU (1) AU2009262022A1 (enExample)
BR (1) BRPI0914734A2 (enExample)
CA (1) CA2728674A1 (enExample)
IL (1) IL210245A0 (enExample)
MX (1) MX2010014280A (enExample)
NZ (1) NZ590385A (enExample)
RU (1) RU2011102743A (enExample)
WO (1) WO2009158620A2 (enExample)
ZA (1) ZA201100225B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US12680139B2 (en) 2009-01-07 2026-07-14 Myriad Genetics, Inc. Cancer biomarkers
US20100248269A1 (en) * 2009-03-30 2010-09-30 New York Blood Center Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9606057B2 (en) 2010-06-01 2017-03-28 Todos Medical Ltd. Biochemical analysis of PBMC
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
WO2012061721A1 (en) * 2010-11-05 2012-05-10 Alleghney-Singer Research Institute Method and system for recommending a decision based on combined entity modeling
EP2707710B1 (en) 2011-05-11 2022-08-17 Todos Medical Ltd. Diagnosis of cancer based on infrared spectroscopic analysis of dried blood plasma samples
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
WO2013036620A1 (en) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Methods and compositions for cytometric detection of rare target cells in a sample
CN104684398A (zh) 2012-08-31 2015-06-03 索隆-基特林癌症研究协会 粒子、方法以及其用途
JP6164678B2 (ja) * 2012-10-23 2017-07-19 国立研究開発法人科学技術振興機構 ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
EP2934600A4 (en) 2012-12-19 2016-08-17 Sloan Kettering Inst Cancer MULTIMODAL PARTICLES, METHOD THEREFOR AND USES THEREOF
EP2958481A4 (en) * 2013-02-20 2017-03-08 Sloan-Kettering Institute for Cancer Research Wide field raman imaging apparatus and associated methods
NZ712575A (en) 2013-03-14 2019-08-30 Castle Biosciences Inc Methods for predicting risk of metastasis in cutaneous melanoma
US9804145B2 (en) 2013-05-28 2017-10-31 Todos Medical Ltd. Infrared analysis of benign tumors
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
WO2015132672A2 (en) * 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016018896A1 (en) 2014-07-28 2016-02-04 Memorial Sloan Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
CA2976769C (en) * 2015-02-17 2023-06-13 Siemens Healthcare Diagnostics Inc. Model-based methods and apparatus for classifying an interferent in specimens
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
EP3317035A1 (en) 2015-07-01 2018-05-09 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
EP3532641A4 (en) * 2016-10-28 2020-06-17 Mao Ying Genetech Inc. METHOD FOR IDENTIFYING THE PRIMARY LOCATION OF METASTASING CANCER AND SYSTEM THEREFOR
CN111094594A (zh) * 2017-07-17 2020-05-01 茂英基因科技股份有限公司 产生复数候选探针和鉴定哺乳动物中细胞类型的方法
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
JP7580210B2 (ja) * 2020-06-15 2024-11-11 三菱重工業株式会社 予兆判定装置、予兆判定方法及びプログラム
US20230092508A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid
EP4445137A4 (en) * 2021-12-08 2025-12-10 Mayo Found Medical Education & Res MELANOMA ASSESSMENT AND TREATMENT
CN116204890B (zh) * 2023-04-28 2023-07-21 浙江鹏信信息科技股份有限公司 一种自适应增强人工智能算法安全的算法组件库
CN117171678B (zh) * 2023-11-02 2024-01-12 北京建工环境修复股份有限公司 一种微生物修复过程中土壤微生物菌群调控方法及系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230767A (en) * 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5018067A (en) * 1987-01-12 1991-05-21 Iameter Incorporated Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US20020038227A1 (en) * 2000-02-25 2002-03-28 Fey Christopher T. Method for centralized health data management
JP2005532780A (ja) * 2001-09-19 2005-11-04 インタージェネティックス インコーポレイテッド 発癌リスク層別化のための遺伝的解析
US7468032B2 (en) * 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20040122296A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
US20050282196A1 (en) * 2004-04-30 2005-12-22 Jose Costa Methods and compositions for cancer diagnosis
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
CA2629793A1 (en) * 2005-11-16 2007-05-24 Marsha A. Moses Method to assess breast cancer risk
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090069196A1 (en) * 2006-03-22 2009-03-12 Mathias Gehrmann Prediction of Breast Cancer Response to Chemotherapy
WO2008030986A2 (en) * 2006-09-06 2008-03-13 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
EP2074226A2 (en) * 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
EP2092075A2 (en) * 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
EP2155897A2 (en) * 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
EP2215261B1 (en) * 2007-10-23 2018-02-21 Clinical Genomics Pty Ltd A method of diagnosing neoplasms
CA2714521A1 (en) * 2008-02-14 2009-08-20 Decode Genetics Ehf Susceptibility variants for lung cancer
US20110053804A1 (en) * 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
WO2009140556A2 (en) * 2008-05-15 2009-11-19 University Of Southern California Genotype and expression analysis for use in predicting outcome and therapy selection
EP4350001A3 (en) * 2009-11-23 2024-06-19 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Also Published As

Publication number Publication date
ZA201100225B (en) 2011-10-26
NZ590385A (en) 2012-11-30
KR20110036056A (ko) 2011-04-06
BRPI0914734A2 (pt) 2015-10-20
IL210245A0 (en) 2011-03-31
AU2009262022A1 (en) 2009-12-30
WO2009158620A3 (en) 2010-06-03
WO2009158620A2 (en) 2009-12-30
MX2010014280A (es) 2011-05-23
EP2307886A2 (en) 2011-04-13
CA2728674A1 (en) 2009-12-30
US20110182881A1 (en) 2011-07-28
CN102132160A (zh) 2011-07-20
JP2011526693A (ja) 2011-10-13

Similar Documents

Publication Publication Date Title
JP2011526693A5 (enExample)
Zaha Significance of immunohistochemistry in breast cancer
Kim et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression
Ito et al. Prognostic significance of ki‐67 labeling index in papillary thyroid carcinoma
Colleoni et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer
Davies et al. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer
RU2011105627A (ru) Отличительные признаки (рс)-детерминанты, связанные с раком предстательной железы, и способы их применения
JP2011528442A5 (enExample)
Guzzo et al. Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance
Yin et al. The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer
Mastrosimini et al. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors
Ji et al. Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer
Hacking et al. Potential pitfalls in diagnostic digital image analysis: experience with Ki-67 and PHH3 in gastrointestinal neuroendocrine tumors
Li et al. AGR2 diagnostic value in nasopharyngeal carcinoma prognosis
CN109975549B (zh) 肿瘤来源IgG在胰腺癌诊断或预后中的用途
JP2008292424A (ja) 腫瘍の検出方法
Miyashita et al. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates
Zhao et al. Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracycline‑based neoadjuvant chemotherapy
RU2011150291A (ru) Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы
Takuwa et al. Characteristic immunophenotype of solid subtype component in lung adenocarcinoma
RU2383339C1 (ru) Способ прогнозирования эффективности неоадъювантной химиотерапии при местнораспространенном раке яичников
Tay et al. Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer
ES3056977T3 (en) Methods of classifying barrett's esophagus
CN109781985A (zh) 用于检测癌症放疗敏感性的试剂盒及其应用
Han ER, PR and HER2 testing in breast cancer

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20120627